Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tanya Korontsvit"'
Autor:
Angel Charles, Christopher M. Bourne, Tanya Korontsvit, Zita E. H. Aretz, Sung Soo Mun, Tao Dao, Martin G. Klatt, David A. Scheinberg
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also trigger T cell-mediated immunity, which might be mediated by changes in human leukocyte antigen (HLA) ligands. We investigated the effects of CDK4/6i, abemaciclib and
Externí odkaz:
https://doaj.org/article/a3a63b8e735c4265b023dcb79db8e5ba
Autor:
Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E. H. Aretz, Tanya Korontsvit, Michael Lau, Michael G. Kharas, Cheng Liu, David A. Scheinberg
Publikováno v:
Blood. 140:861-874
Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool o
Autor:
Tanya Korontsvit, Michael G. Kharas, Martin G. Klatt, Megan M. Dacek, David A. Scheinberg, Hanzhi Luo, Zita E.H. Aretz, Christopher M. Bourne, Tao Dao, Thomas J. Gardner, Cheng Liu, Leila Peraro, Zhiyuan Yang, Sung Soo Mun, Jianying Liu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S447-S448
Context Target identification for CAR-T cell therapies, especially shared targets among different malignancies, remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of c
Autor:
Tanya Korontsvit, Sung Soo Mun, Martin G. Klatt, Zita E.H. Aretz, Christopher M. Bourne, Angel Charles, Tao Dao, David A. Scheinberg
PurposeCyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also demonstrate antineoplastic activity through triggering T cell-mediated immunity. One of the potential mechanisms responsible for this immunological effect migh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67645e796fa18d9124c9ce282b408ce2
https://doi.org/10.1101/2020.06.18.157800
https://doi.org/10.1101/2020.06.18.157800
Autor:
Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E.H. Aretz, Tanya Korontsvit, Michael G. Kharas, Cheng Liu, David A. Scheinberg
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S257
Autor:
Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E.H. Aretz, Tanya Korontsvit, Michael G. Kharas, Cheng Liu, David A. Scheinberg
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S204
Publikováno v:
Blood. 106:3512-3512
The recent identification of the JAK2 V617F mutation in myeloproliferative diseases including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis has the potential to serve as a new therapeutic target for these disorders. We hyp
Autor:
Tanya Korontsvit, Tao Dao, Rena May, Kappel Barry, Javier Pinilla, M. Gómez, Victoriya Zakhaleva, David A. Scheinberg
Publikováno v:
Blood. 104:4689-4689
Imatinib mesylate is now standard treatment for chronic myelogenous leukemia. In spite of its high efficacy in controlling the disease, residual bcr-abl cells measured by RT-PCR are still detectable in more than 95% of the patients treated with this